Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Khk4827 140mg Sc

Related Conditions

Often studied with 14 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Phase 3 (2)
Phase 4 (1)

Trial Status

Completed3
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT01680159Phase 3Completed

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

NCT02052609Phase 3Completed

A Phase 3 Clinical Study of KHK 4827

NCT05144165Unknown

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

NCT04183881Phase 4Completed

A Phase 4 Clinical Study of Brodalumab

Showing all 4 trials

Research Network

Common Treatments

  • Khk4827 140mg Sc1
  • Khk4827 210mg Sc1
  • Ta6501
  • Brodalumab1
  • Experts Consensus1

Active Sponsors

  • Kyowa Kirin Co., Ltd.2
  • Centre of Evidence of the French Society of Dermatology1
  • Tanabe Pharma Corporation1

Top Investigators

Related Conditions

  • Psoriatic Arthritis3
  • Psoriasis Vulgaris3
  • Pustular Psoriasis Palmaris Et Plantaris2
  • Psoriasis Inverse1
  • Psoriatic Nail1

Activity Timeline